Mesenchymal Stem cells in the context of canine atopic dermatitis: A Review

• Autor(a) principal: REIS,Bruna Padilha Zurita Claro dos
• Data de Publicação: 2021
• Outros Autores: ORGE,Iasmim Diniz, SAMPAIO,Gabriela Louise de Almeida, DALTRO,Sérgio Ricardo Teixeira, SANTOS,Ricardo Ribeiro dos, MEIRA,Cássio Santana, SOARES,Milena Botelho Pereira
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Revista Brasileira de Saúde e Produção Animal
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1519-99402021000100700
• topic: dermatology; inflammatory; skin diseases; canine atopic dermatitis

ABSTRACT Canine atopic dermatitis (CAD) is a chronic inflammatory skin disease and has a high frequency among dermatological diseases. The interaction of genetic factors, skin and environmental conditions affect the expression of the disease, developing a complex pathology. Current multimodal treatment has numerous adverse effects and variations in its efficacy and safety, demonstrating the need to develop safe and effective therapeutic resources for patients with CAD. Mesenchymal stem cells (MSCs) are multipotent cells, with special characteristics, such as self-renewal, immunomodulatory properties, and de-differentiation, making them useful for several clinical problems. The discovery of the immunosuppressive effect of MSCs on T cells has opened the potential for new perspectives with its use as a therapeutic agent for immune diseases, such as CAD. The scarce number of research using the MSC as a treatment for CAD result in the lack of knowledge about the benefits and possible protocols to be followed for the use of this cell therapy. In this review, we highlighted the clinical studies and potential biological mechanisms of MSC-based cell therapy effects attenuating canine atopic dermatitis compared to conventional treatment, which might lead to a safe improvement of the animal’s clinical condition in a short period without causing adverse effects.